Overview

Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma

Status:
Active, not recruiting
Trial end date:
2021-12-20
Target enrollment:
Participant gender:
Summary
Controlled, randomized phase III study, with the intent of optimizing the treatment of not metastatic Ewing Sarcoma. The patients will be randomized into 2 arms: standard treatment vs intensive treatment. Both arms will receive an induction treatment followed by surgery (wherever is possible) and/or radiotherapy. The maintenance treatment will be different on the basis of the response to the induction treatment (good or poor)
Phase:
Phase 3
Details
Lead Sponsor:
Italian Sarcoma Group
Treatments:
Busulfan
Cyclophosphamide
Dactinomycin
Doxorubicin
Etoposide
Etoposide phosphate
Ifosfamide
Isophosphamide mustard
Liposomal doxorubicin
Melphalan
Vincristine